Isthmus Partners LLC Sells 33,200 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Isthmus Partners LLC cut its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 20.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 132,047 shares of the medical equipment provider’s stock after selling 33,200 shares during the period. Isthmus Partners LLC’s holdings in BioLife Solutions were worth $3,306,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. bought a new position in BioLife Solutions in the second quarter valued at about $35,000. Quest Partners LLC bought a new position in shares of BioLife Solutions during the third quarter worth about $57,000. GAMMA Investing LLC raised its position in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of BioLife Solutions during the second quarter worth about $122,000. Finally, Summit Global Investments bought a new position in shares of BioLife Solutions during the third quarter worth about $228,000. 93.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BLFS. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. TD Cowen lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.50.

BioLife Solutions Trading Up 0.4 %

Shares of BioLife Solutions stock opened at $27.16 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The stock has a 50 day moving average price of $24.16 and a two-hundred day moving average price of $23.16. The stock has a market capitalization of $1.26 billion, a PE ratio of -25.62 and a beta of 1.88.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at $7,593,412.40. This trade represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,644 shares of company stock valued at $1,527,503. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.